The ErbB2 receptor tyrosine kinase has been implicated as a critical growth factor receptor in both normal development and cancer. Amplification and overexpression of this receptor is observed in 20-30% of all human breast cancers and is inversely correlated with patient survival. Studies with transgenic mice have established that elevated expression of erbB2 in mammary epithelium can directly induce mammary carcinomas. Although these studies confirmed a role for ErbB2 in breast cancer induction, the precise role of ErbB2 in normal mammary gland development remained to be elucidated due to the embryonic lethality associated with the null mutation. Here, we demonstrate that the mammary-specific ablation of erbB2 through Cre-mediated recombination leads to a striking ductal elongation defect. In addition to the observed elongation defect, we noted that branching in the adult mammary gland was also reduced. Despite these perturbations in virgin mammary gland morphogenesis, targeted disruption of erbB2 had little impact on the ability of these animals to lactate. Taken together, these observations indicate that erbB2 plays a critical role in the initial stages of mammary gland morphogenesis. Oncogene (2005) 24, 932-937.
The ErbB2 receptor tyrosine kinase has been implicated as a critical growth factor receptor in both normal development and cancer. Amplification and overexpression of this receptor is observed in 20-30% of all human breast cancers and is inversely correlated with patient survival. Studies with transgenic mice have established that elevated expression of erbB2 in mammary epithelium can directly induce mammary carcinomas. Although these studies confirmed a role for ErbB2 in breast cancer induction, the precise role of ErbB2 in normal mammary gland development remained to be elucidated due to the embryonic lethality associated with the null mutation. Here, we demonstrate that the mammary-specific ablation of erbB2 through Cre-mediated recombination leads to a striking ductal elongation defect. In addition to the observed elongation defect, we noted that branching in the adult mammary gland was also reduced. Despite these perturbations in virgin mammary gland morphogenesis, targeted disruption of erbB2 had little impact on the ability of these animals to lactate. Taken together, these observations indicate that erbB2 plays a critical role in the initial stages of mammary gland morphogenesis. Keywords: ErbB2; mammary gland; mouse models; epithelium ErbB2 (Neu, HER2) is a member of the epidermial growth factor receptor (EGFR) family of receptor tyrosine kinases. Amplification and overexpression of the erbB2 proto-oncogene is observed in 20-30% of human breast cancers and is inversely correlated with patient survival (Slamon et al., 1987 (Slamon et al., , 1989 Andrulis et al., 1998) . Direct evidence supporting a role for ErbB2 in mammary tumorigenesis is derived from observations made with transgenic mice. Mammary epithelial-specific expression of activated erbB2 results in the rapid induction of metastatic multifocal mammary tumors (Muller et al., 1988; Bouchard et al., 1989; Guy et al., 1996; Siegel et al., 1999) . While the role of the ErbB2 in tumorigenesis has been well described, the determination of the role of this receptor in mammary gland development has been hampered by the fact that germline ablation of erbB2 is associated with embryonic lethality. Indeed, mice lacking functional erbB2 die at 10.5 days of embryogenesis due to both cardiac and neural defects (Lee et al., 1995) . One indication that ErbB2 may be involved in mammary development was the observation that the mammary epithelium in the transgenic Neu mice had a reduced rate of penetration into the fat pad, but this may be due to regulation of the sex steroid response (Mukherjee et al., 2000) .
To derive genetically engineered mice that lack ErbB2 in the mammary epithelium, we used knockin mice that carry loxP flanked rat erbB2 cDNA in the first coding exon of the endogenous mouse erbB2 gene (Andrechek et al., 2002) . We have demonstrated that mice homozygous for this loxP flanked erbB2 cDNA (ErbB2 Flox/Flox ) are viable and exhibit no obvious phenotypic abnormalities. However, due to the inefficient translation of the inserted erbB2 cDNA, ErbB2
Flox/Flox mice express 10% of wild-type ErbB2 (Andrechek et al., 2002) . Despite the low level of ErbB2 expression, these ErbB2
Flox/Flox mice exhibit normal mammary gland development and were used as a control in the work described herein. To generate a mammary-specific knockout of erbB2, we interbred the ErbB2
Flox/Flox mice with a separate transgenic strain that expresses Cre recombinase under the transcriptional control of the MMTV promoter/enhancer (Andrechek et al., 2000) . We previously demonstrated that this MMTV/Cre strain expresses elevated levels of Cre recombinase in a mammary-specific manner. However, since the MMTV promoter/enhancer is often methylated in strains other than FVB (Chaillet et al., 1995; Zhou et al., 2001) , the SV129/Balb/c ErbB2 Flox/Flox mice were interbred onto a syngenic FVB background. In order to generate a mammary-specific ablation of ErbB2, ErbB2
Flox/Flox mice were interbred with the MMTV/Cre transgenics ( Figure 1a) . To monitor the extent of functional excision, genomic DNA was prepared from the various genotypic combinations and was subjected to a Southern blot analyses with probes that detect the excised and unexcised products as well as the presence of the Cre transgene. Excision was observed both in the ErbB2 WT/Flox MMTV-Cre and ErbB2 Flox/Flox MMTV-Cre mice (Figure 1b, lanes 3-5) . Owing to the fact that mammary glands are comprised of both epithelial and stromal tissue, the incomplete excision observed in the ErbB2
Flox/Flox MMTV-Cre mice likely reflects the remaining stromal tissue that does not express Cre recombinase.
To confirm that observed excision was confined to the mammary epithelium, we crossed the MMTV/Cre mice to mice harboring a Cre responsive b-galactosidase reporter (GTRosa26) (Soriano, 1999) . The presence of the GTRosa26 allele enabled us to monitor at the individual cell level whether a Cre-mediated excision event leading to the production of b-galactosidase expression has occurred. Low magnification of the GTRosa mammary gland wholemount after standard X-gal staining revealed that there was no appreciable background staining in the mammary gland ( Figure 2a ). Analyses of mice carrying both the MMTV/Cre and GTRosa allele revealed widespread mammary epithelialspecific excision through the detection of b-galactosidase activity (Figure 2b ). Higher magnification of the boxed areas (Figure 2c and d) revealed that with the addition of the Cre transgene, the majority of the mammary epithelial cells exhibited staining (Figure 2d) . In crosssections no significant b-galactosidase activity was detected in the mammary epithelium from the parental GTRosa strain (Figure 2e ). Conversely, excision resulting in staining was observed in a large percentage of luminal epithelial cells in the MMTV/Cre GTRosa sections ( Figure 2f ). Importantly, when this analysis was repeated at 3 weeks of age, staining was observed in the MMTV/ Cre GTRosas ( Figure 2g ). Further, in these wholemounts, staining is observed in the TEB, illustrating that the Cre is expressed in the mammary epithelium from an early age. Taken together with the molecular analyses, these observations indicate that the MMTV/Cre transgene is capable of removing erbB2 in the majority of mammary epithelial cells. Since alterations of steroid hormone levels could influence the interpretation of a mammary phenotype, the expression of Cre recombinase in the ovaries was examined. While b-galactosidase activity was readily detected in the mammary control (Figure 2f ), no excision whatsoever was detected in the ovarian sections (Figure 2h ). These data are consistent with previously published work characterizing the MMTV/Cre mice (Andrechek et al., 2000) .
Given the ability of MMTV/Cre transgene to efficiently target the mammary epithelium, we assessed whether targeted disruption of ErbB2 in mammary epithelium affected normal mammary gland development. Examination of hematoxylin-stained mammary gland wholemounts derived from virgin female mammary glands at 3 weeks revealed striking differences in the extent of mammary gland ductal outgrowth between the littermate control ErbB2
Flox/Flox and the ErbB2 Wholemount examination of the extent of development of 4-week virgin glands from ErbB2
Flox/Flox and ErbB2
Flox/Flox MMTV/Cre mice revealed comparable defects in both ductal outgrowth and branching morphogenesis. In contrast to the well-developed ductal network in the ErbB2
Flox/Flox control mammary gland (Figure 4a ), the ducts in the conditional null mice have moved half the distance from the nipple to the lymph node and clearly lag behind the control (Figure 4b ). However, in contrast to the 3-week time point (Figure 3) , by 4 weeks the conditional null ErbB2 mammary gland Figure 1 Mammary-specific ErbB2 ablation. Exon one of the wild-type erbB2 allele was replaced by a loxP flanked cDNA followed by a selectable marker (a). With the introduction of the MMTV-Cre transgene, the loxP flanked cDNA should be removed in a mammary-specific fashion, resulting in a tissue-specific null allele. In a Southern, using a HindIII digest, the floxed allele should be detected at 10 kb and the null allele at 6 kb (a). Mice were interbred and DNA was extracted from the mammary glands of adult ErbB2
Flox has developed TEBs (Figure 4b ). The quantification of the extent of the growth into the epithelium is also shown (Figure 4c) , and clearly illustrates the developmental delay of the conditional null mammary gland (n ¼ 5).
Comparative wholemount analyses of the mammary glands at 12 weeks of age on the ErbB2
Flox/Flox control and ErbB2
Flox/Flox MMTV/Cre mice still revealed significant differences in the degree of mammary gland development (Supplementary Figure 1) . In contrast to the control glands, which have completely filled the mammary fat pad, the mammary epithelium derived from ErbB2
Flox/Flox MMTV/Cre mice still have not yet completely penetrated the fat pads. Comparison of the control and conditional null mammary glands at a higher magnification revealed that the lateral branching is also markedly reduced in the conditional null glands and is more accentuated at the periphery of the mammary gland. However, examination of later adult stages of ductal development revealed that mammary development in the ErbB2
Flox/Flox MMTV/Cre mice reaches completion (data not shown). Moreover, ErbB2
Flox/Flox MMTV/Cre mice were observed to suckle their offspring normally through numerous cycles of lactation and involution with no abnormal runting of the pups. Consistent with these observations, mammary glands from the ErbB2
Flox/Flox MMTV/Cre mice throughout pregnancy, lactation and involution revealed no significant differences between control and ErbB2-deficient mammary glands (data not shown). Taken together, these results argue that ErbB2 plays a critical role in the early stages of ductal outgrowth and development but is dispensable for subsequent functional differentiation of the gland.
To determine whether molecular changes persisted in the differentiated mammary gland, adult mammary epithelium was collected from ErbB2
Flox/Flox and ErbB2-Flox/Flox MMTV/Cre mice and was used in a gene expression analysis. RNA from 10 mice from each line was pooled into two groups and was analysed through an Affymetrix chip analysis. A portion of the resulting fold differences above a twofold cutoff are shown in Table 1 . Of note is WDNM1, which is downregulated in the conditional null, suggesting that a population of epithelial cells is either under-represented or absent. Given that WDNM1 is also overexpressed in ErbB2-expressing mammary tumors (Andrechek et al., 2003) , it is conceivable that the observed lower levels of WDNM1 reflect the absence of ErbB-2-induced mammary Figure 2 Mammary epithelial-specific X-gal staining. X-gal staining was completed on ROSA (a) and MMTV-Cre ROSA (b) adult mammary glands. This analysis revealed that while there was no detectable staining in the controls (a), excision mediated by the Cre transgene caused b-galactosidase expression throughout the mammary epithelium. The boxed regions are magnified and show the extent of excision caused by the Cre transgene (compare c and d). In cross-section, while there is no staining in the ROSA control (e), the extent of staining in the ROSA MMTV-Cre mice is seen to affect a majority of the luminal epithelial cells (f). When the assay was repeated on ROSA MMTV-Cre mice at 3 weeks of age, widespread staining is observed throughout the ductal network and in the terminal end buds (g). To determine that excision was limited to the mammary gland, X-gal staining on a ROSA MMTV-Cre ovary was completed. This revealed that there was no staining, indicating that MMTV-Cre directs mammary-specific excision (h) epithelial cell type that may play a role in ductal morphogenesis. Other sets of genes that appear to be elevated, such APAF1, are associated with apoptotic cell death. It is possible that elevated epithelial apoptosis may in part account for the ductal outgrowth defect.
Although elevated expression of ErbB2 has previously been noted in a large percentage of human breast cancers (Slamon et al., 1987 (Slamon et al., , 1989 , the role it plays in regulating the normal development of the mammary gland was not well understood. In this study, we have demonstrated that ErbB2 is required for the initial stages of ductal outgrowth. The results we have reported for the outgrowth defect are consistent with a mammary epithelial autonomous phenotype since this is a mammary epithelial-specific deletion. To rule out the possibility of a hormonal imbalance that would modify the phenotype, we also examined the ovaries for excision by RNase protection analysis (Andrechek et al., 2000) and by interbreeding to the ROSA reporter strain. These results indicate that steroid levels should not be affected and the observed defect should be cell autonomous. Moreover, when mammary epithelium lacking ErbB2 is implanted into a wild-type fat pad, the same ductal Flox/Flox (a) and ErbB2 Flox/Flox MMTV/Cre (b) mammary glands were compared at 3 weeks of age after hematoxylin staining. While the control mammary gland has formed terminal end buds (open arrowheads) by this stage and has begun to expand into the fat pad (a), the conditional null is developmentally delayed. Few terminal end buds were observed at 3 weeks in the conditional null mice and the ductal development was not seen to expand past a rudimentary tree with few branches. Quantification of the number of terminal end buds from the control and the conditional deletion is also shown (c) Figure 4 Ductal elongation defects in ErbB2 null glands. Wholemounts were examined at 4 weeks of age for both ErbB2
Flox/Flox control (a) and ErbB2
Flox/Flox MMTV/Cre (b) mice. By 4 weeks of age, the control mammary epithelium has grown from the nipple to the lymph node (LN) with the terminal end buds visible at the leading edge of growth. In contrast, the conditional deletion of ErbB2 (b) is delayed in the outgrowth, only approaching the halfway point from the nipple to the lymph node. However, unlike the 3-week time point, these mammary glands now show the presence of normal terminal end buds. The quantification of the growth from the nipple to the midpoint of the lymph node is shown (c) delay phenotype was observed (personal communication, Amy Jackson-Fisher and David Stern).
Similar ductal outgrowth defects have also been noted in mice bearing mutant members of the EGFR family. For example, waved-2 mice carrying a kinase impaired EGFR allele exhibit comparable ductal defects (Fowler et al., 1995) . However in contrast to cell autonomous requirement for ErbB2 function, transplantation of EGFR null tissues has revealed that EGFR functions primarily in the stroma during the phase of ductal outgrowth (Sebastian et al., 1998) . Recent observations from crystallization experiments showing that ErbB2 homodimers will not readily form due to electrostatic repulsion (Garrett et al., 2003) suggest that preventing ErbB2 heterodimers with ErbB3 or ErbB4 in the mammary epithelium may mediate the phenotype that we have observed. Although a mammary-specific inactivation of ErbB4 has been reported, excision in this strain was directed by the WAP-Cre transgene and the authors were therefore unable to examine ductal outgrowth (Long et al., 2003) . Although dominant negative ErbB4 experiments did not reveal a role for ErbB4 in ductal extension , related ErbB2 dominant negative experiments did not uncover the same effects that we observed . Moreover, mammary implantation of the ErbB3 and ErbB4 ligand Heregulin resulted in increased TEB formation (Jones et al., 1996) . Thus, the heterodimerization partners for ErbB2 in ductal extension may be either ErbB3 or ErbB4 and this issue will be resolved by further mammaryspecific ablations. Indeed, it is also possible that these other family members or downstream signaling molecules are compensating for the loss of ErbB2 in the mice and may be mitigating the effect of the loss of the receptor. Indeed, the hypomorphic nature of the knock-in allele may also be compensated by other family members but it is important to note that the ErbB2
Flox/Flox mice did not have a mammary defect and were consistently used as controls in these experiments. Future crosses with other family members to create combination mammary-specific deletions will address the issue of compensation for the loss of ErbB2 in ductal development.
Although ErbB2 function appears to be critical for the early stages of mammary epithelial outgrowth, female animals bearing the mammary-specific knockout of ErbB2 are capable of lactation, suggesting that ErbB2 function is dispensable for functional differentiation of the mammary gland. However, the importance of the EGFR family in lactation has been previously demonstrated. For example, the mammary-specific knockout of ErbB4 resulted in a profound defect in functional differentiation of mammary epithelium (Long et al., 2003) . Moreover, the waved-2 mice, which harbor an impaired EGFR allele, also have lactational defects (Fowler et al., 1995) . Taken together with our observations, these data suggest that ErbB4 homodimers or heterodimers consisting of EGFR or ErbB3 but not ErbB2 are important EGFR family receptor combinations for functional differentiation and lactation.
Given that the mammary-specific deletion of ErbB2 resulted in a reduced potential for extension of the ductal network into the fat pad, it is interesting to note that elevated expression of ErbB2 in human breast cancer is associated with the metastatic progression of the disease. Knowing the potential importance of ErbB2 in regulating pathways involved in tissue remodeling and invasion, it is conceivable that developmental defects observed in the ErbB2 null mammary glands reflect the importance of ErbB2 in the progression of metastatic breast cancer. The future identification and elucidation of these pathways may offer therapeutic targets for the treatment of breast cancers. Flox/Flox MMTV/Cre adult mammary glands illustrates molecular differences. Positive fold change results represent genes that were expressed at a higher level in the conditional knockout. A two fold change was used as a cutoff point for genes that were examined. Results were confirmed by quantitative RT-PCR analysis. Interestingly WDNM1 expression was downregulated in the conditional knockout while it is often upregulated in ErbB2 mediated tumors
